Surveys of more than 1,000 Italian patients and clinicians uncover why oral steroid use remains widespread in asthma care, revealing gaps in guideline adherence, patient education, and access to advanced biologic therapies.
Study:
HILLERØD, Denmark, October 15, 2025 – FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced that 100 percent of its existing electricity needs at the Hillerød, Denmark, commercial-scale biologics manufacturing site are now covered by solar-power through Power Purchase Agreements (PPA).
The solar-powered electricity consumption is facilitated through a previously announced 10-year PPA to offtake 40 GWh of renewable energy annually from a nearby solar park. The solar park announced new ownership by the energy group Andel in 2025.
The solar park is expected to have an annual production capacity of 110 GWh equivalent to the annual electricity consumption of 28,000 Danish households. In addition to offsetting the energy consumption of the Hillerød site, the solar park will increase the amount of renewable energy in the Danish power grid.
The Hillerød site currently has 12 x 20,000 liters (L) mammalian cell culture bioreactors to support biopharma manufacturing. As part of a previously announced investment to create the largest end-to-end CDMO in Europe, the site will add 8 x 20,000 L bioreactors and two downstream processing streams — increasing to a total footprint of approximately 51,500 m². As part of the target to substitute fossil fuels with renewable energy in production, this further expansion will be fully electrified, as FUJIFILM Biotechnologies is installing electric steam boilers instead of natural gas fired boilers.
“I’m proud of the significant milestone in utilizing solar-powered electricity. This achievement reflects our strong commitment to sustainability and our Partners for the Planet plan,” said Christian Houborg, senior vice president, and Hillerød site head, FUJIFILM Biotechnologies. “As a leader in biopharma manufacturing, we aim to set high standards in sustainable operations within biopharma manufacturing.”
The PPA and other renewable energy initiatives at the Denmark site are part of FUJIFILM Biotechnologies’ Partners for the Planet plan to convert operations to renewable electricity and achieve a 50 percent reduction in (Scope 1 & 2) GHG emissions by Fiscal Year 2030 (compared to baseline in Fiscal Year 2019), and to focus on GHG emissions reduction throughout the supply chain.
In her “Life of a Song” (FT Weekend, September 27), Natalie Perman rightly celebrates Chris Kenner’s 1962 “Land of 1000 Dances”. As she notes, the song has been most closely associated with Cannibal & the Headhunters, but it was the…
The American space agency has plans to send humans to the Moon once again as part of its Artemis mission. The 10-day Artemis II test flight is set to launch by April 2026, and will be the first crewed flight to the Moon under the Artemis program….
HashiCorp has issued a warning that traditional secret scanning tools are failing to keep up with the realities of modern software development.
In a new blog post the company argues that current approaches—often reliant on…
Cancer is a significant public health concern worldwide, with a rapidly growing disease burden. According to the most recent estimates from the World Health Organization (WHO), the global new cancer cases will exceed 35 million by…
In the article, Justine emphasizes the unique focus California places on employee and applicant data, noting that the CPPA enforcement signals a shift toward more customized and transparent privacy disclosures for employees and applicants. She also highlighted the need for harmonized governance across people, process, and technology to mitigate data-driven risk. As enforcement ramps up, Justine’s insights underscore the urgency for businesses operating in California to reassess their privacy compliance strategies.
Read the full article in The Recorder: California Privacy Watchdog’s Record Fine Against Tractor Supply Company Signals ‘Escalating’ Enforcement Trend | Law.com
The latest Blancpain releases are classical watchmaking refined with a purpose. Long before the Villeret collection officially gained its name in 2003, Blancpain had already set the template in the early 1980s with a…
Quantitative angiogenesis-based ultrasound biomarkers can differentiate between radial scar lesions and breast cancer, suggest findings published October 14 in The Breast.
A team led by Azra Alizad, MD, from the Mayo Clinic in Rochester, MN,…